For instance, in a comparative preclinical study, the SSTR2 antagonist 177Lu-OPS201 showed superior tumor uptake and longer tumor retention in SSTR2-expressing xenografts compared with the agonist [177Lu]Lu-DOTATATE (25). This evidence concerns the gene SSTR2 and neoplasm.